Key result
MYH9-rs3752462 CT genotype is linked to ~8-fold higher CKD risk in hypertensive patients.
Why the study?
Polymorphisms in the MYH9 gene have been associated with CKD in African- and European-derived populations, but their spectrum among Ghanaian hypertensive patients was not investigated.
Case-Control (n=264)
No
Odds Ratio: 7.82 (95% CI 3.81–16.04)
Absolute Event Rate: 80.3% vs 31.8%
p-value: p=<0.001
The MYH9-rs3752462 polymorphism is significantly associated with chronic kidney disease among Ghanaian hypertensive patients, with the CT genotype increasing risk and the TT genotype being protective.
MYH9 variants associate with CKD in Ghanaian hypertensives; leaves open clinical utility pending larger prospective validation.
Background Chronic kidney disease (CKD) is a significant comorbidity among hypertensive patients. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) have been demonstrated to be significantly associated with CKD, among African- and European-derived populations. We investigated the spectrum of MYH9-associated CKD among Ghanaian hypertensive patients. Methods The study constituted a total of 264 hypertensive patients. Hypertensive patients with glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 (CKD-EPI formula) or clinically diagnosed were defined as case subjects (n = 132) while those with eGFR ≥60 ml/min/1.73m2 were classified as control subjects (n = 132). Demographic data were obtained with a questionnaire and anthropometric measurements were taken. Five (5) millilitres (ml) of venous blood was drawn from study subjects into gel and EDTA vacutainer tubes. Two (2) mL of EDTA anticoagulated blood was used for genomic DNA extraction while three (3) mL of blood was processed to obtain serum for biochemical measurements. Genotyping of MYH9 polymorphisms (rs3752462) was done employing Tetra primer Amplification Refractory Mutation System (T-ARMS) polymerase chain reaction (PCR). Spot urine samples were also collected for urinalysis. Hardy-Weinberg population was assessed. Logistic regression models were used to assess the associations between single nucleotide polymorphisms and CKD. Results The cases and control participants differed in terms of age, sex, family history, and duration of CKD (p-value < 0.001). The minor allele frequencies of rs3752462 SNP were 0.820 and 0.567 respectively among the control and case subjects. Patients with the heterozygote genotype of rs3752462 (CT) were more likely to develop CKD [aOR = 7.82 (3.81–16.04)] whereas those with homozygote recessive variant (TT) were protective [aOR = 0.12 (0.06–0.25)]. Single nucleotide polymorphism of rs3752462 (CT genotype) was associated with increased proteinuria, albuminuria, and reduced eGFR. Conclusions We have demonstrated that MYH9 polymorphisms exist among Ghanaian hypertensive patients and rs3752462 polymorphism of MYH9 is associated with CKD. This baseline indicates that further longitudinal and multi-institutional studies in larger cohorts in Ghana are warranted to evaluate MYH9 SNP as an independent predictor of CKD among hypertensive patients in Ghana.
No takes yet. Share an insight, caveat, or question.
Owiredu et al. (2020) conducted a case-control in Chronic kidney disease in hypertensive patients (n=264). MYH9-rs3752462 polymorphism (CT genotype) vs. MYH9-rs3752462 wild type / other genotypes was evaluated on Chronic kidney disease (aOR 7.82, 95% CI 3.81-16.04, p=<0.001). The heterozygote genotype (CT) of the MYH9-rs3752462 polymorphism was associated with a significantly increased odds of chronic kidney disease among Ghanaian hypertensive patients (aOR 7.82).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: